Moderna RSV vaccine more than 80% effective, study shows

Moderna Inc.
mRNA,
+9.25%

The experimental respiratory syncytial virus vaccine is 84% ​​effective against lower respiratory tract illnesses linked to the virus, according to phase 3 study data published in the New England Journal of Medicine. The vaccine, which uses mRNA technology also used in COVID shots, was studied in adults 60 and older and did not result in any obvious safety concerns, according to the study. In the United States, approximately 60,000 to 160,000 older adults are hospitalized each year due to RSV infection, according to the Centers for Disease Control and Prevention. Moderna is preparing for a commercial launch of the vaccine in 2024, the company said in a statement Friday. This shot would rival that of Pfizer Inc.
PFE,
-1.99%

RSV Vaccine Abrysvo and GSK PLC
GSK,
+0.65%

Arexvy, which are already on the market. Moderna shares gained 1.9% premarket Friday and are down 52% year to date, while the S&P 500
SPX,
+0.26%

is up 22.9%.